Bluebid Bio Shares Fall 4.3% After Gene Therapy Update
October 19, 2015 at 19:32 PM EDT
Shares of Bluebird Bio fell 4.3% on heavier-than-usual volume after the company announced that one patient on old-generation gene therapy required two blood transfusions due to anemia.